top of page

Search

AI in biotech with Generate Biomedicines’ Mike Nally

blonca9
Jan 11, 2023
1 min read

Updated: Jun 17, 2023

Generate Biomedicine's Mike Nally describes how AI might impact biotech in the future at #JPM23.

Recent Posts

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page